Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. The HemoScreen hematology point-of-care device is suitable for rapid evaluation of acute leukemia patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Performance of the Sysmex White Precursor Channel to discover circulating leukemic blast cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Evaluation of the HemoCue WBC DIFF in leukopenic patient samples

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Hereditary xerocytosis and familial haemolysis due to mutation in the PIEZO1 gene: a simple diagnostic approach

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Gene expression profiling (GEP) risk models in multiple myeloma are based on 3'-end microarrays. We hypothesized that GEP risk signatures could retain prognostic power despite being translated and applied to whole-transcript microarray data.

METHODS: We studied CD138-positive bone marrow plasma cells in a prospective cohort of 59 samples from newly diagnosed patients eligible for high-dose therapy (HDT) and 67 samples from previous HDT patients with progressive disease. We used Affymetrix Human Gene 1.1 ST microarrays for GEP. Nine GEP risk signatures were translated by probe set match and applied to our data in multivariate Cox regression analysis for progression-free survival and overall survival in combination with clinical, cytogenetic and biochemical risk markers, including the International Staging System (ISS).

RESULTS: Median follow-up was 66 months (range 42-87). Various translated GEP risk signatures or combinations hereof were significantly correlated with survival: among newly diagnosed patients mainly in combination with cytogenetic high-risk markers and among relapsed patients mainly in combination with ISS stage III.

CONCLUSION: Translated GEP risk signatures maintain significant prognostic power in HDT myeloma patients. We suggest probe set matching for GEP risk signature translation as part of the efforts towards a microarray-independent GEP risk standard. (ClicinalTrials.gov identifier: NCT00639054).

Original languageEnglish
JournalInternational Journal of Laboratory Hematology (Print Edition)
Volume38
Issue number3
Pages (from-to)298-307
Number of pages10
ISSN1751-5521
DOIs
Publication statusPublished - Jun 2016

    Research areas

  • Journal Article

ID: 49300361